Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe

Aprepitant Reduces Cough Severity in Patients with Lung Cancer

TOP - February 2016, Vol 9, No 1 - Lung Cancer

Boston, MA–In a first-of-its-kind study, aprepitant (Emend), a centrally acting neurokinin (NK)-1 antagonist indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV), led to a reduction in cough frequency and an improvement in the objective and subjective measures of cough in patients with lung cancer. The study was conducted in the United Kingdom and was presented at the 2015 Palliative Care in Oncology Symposium. In September 2015, aprepitant capsules received an expanded indication for CINV in combination with other antiemetic therapies for use in patients aged ≥12 years and those aged <12 years who weigh at least 30 kg.

"Cough is a complex symptom that has a significant impact on the quality of life of patients, and it is very severe in lung cancer patients," said Amelie Sylvia Mary Harle, MD, PhD, a medical oncologist at the Christie NHS Foundation Trust, Manchester, England.

Approximately 50% of patients with lung cancer report that their cough is severe enough to warrant treatment, and approximately 25% report a painful cough that affects their quality of life.

"The neuronal pathways that control cough are complex," said Dr Harle. "They involve the peripheral nervous system and the central nervous system, but our understanding of these complex pathways is beginning to emerge."

Currently, no evidence-based therapies exist for the treatment of cough in patients with lung cancer. However, the NK-1 pathway is implicated in cough, and aprepitant is a centrally acting NK-1 antagonist currently indicated for the treatment of CINV.

According to Dr Harle, centrally acting NK-1 receptor antagonists have never been tested as a novel antitussive agent in humans, so she and her coinvestigators sought to assess aprepitant's capability to act as an antitussive, using objective daytime ambulatory cough monitoring as the primary end point.

Overall, 20 patients were examined (mean age, 66 years). Of these, 70% were former smokers, 25% current smokers, and 5% never-smokers; 16 had non-small–cell lung cancer, 10 had advanced-stage disease, and 4 were receiving anticancer therapy.

"We used a crossover design to enable a small sample size, because cough varies so much between individuals, and we wanted patients to act as their own controls," said Dr Harle.

The participants received 125 mg of aprepitant on day 1 and 80 mg on days 2 and 3 or matched placebo, after which all the assessments were repeated. After a 3-day washout, patients crossed over to alternative treatment of aprepitant or to placebo for 3 days (days 7-9). The assessments were again repeated, and a toxicity assessment was performed at days 13 to 14.

The primary end point was the comparison of change from baseline in daytime cough counts for aprepitant versus for placebo. "This outcome measure was an objective quantification of cough, using cough recordings from which we could develop a cough frequency," said Dr Harle. The secondary end point was the comparison of change from baseline in cough scores. "These were the subjective assessments, using validated cough questionnaires and standard oncology tools assessing cough," she added.

Significant Reduction in Cough Frequency

"Aprepitant led to a statistically significant reduction in cough frequency," Dr Harle reported. The daytime cough frequency was 15.9 coughs per hour at baseline, 12.8 with aprepitant, and 16.2 with placebo (P = .03). A significant reduction in all cough scores was also demonstrated.

"Regarding the subjective measures, the effect was modest, but interestingly, patients were able to report a difference in all 4 of the measurements that we used," Dr Harle stated. "Even the physician-rated scale, which is quite a blunt instrument, showed improvement."

The adverse events were minimal, and the investigators found aprepitant to be well-tolerated.

This trial is the first to measure the efficacy of aprepitant as a novel antitussive using validated subjective and objective cough measurements in patients with lung cancer. It is also the first trial to investigate a centrally acting NK-1 antagonist in humans. Treatment with aprepitant was associated with significant improvements in objective and subjective scores, suggesting that the NK-1 pathway may be a key component of cough mechanisms in patients with lung cancer.

"We hope these data will inform the design of a definitive trial in the future," said Dr Harle.

Related Items
Sotorasib Achieves Durable Responses in Patients with Metastatic NSCLC and KRAS Mutation
Patricia Stewart
TOP - September 2022 Vol 15, No 5 published on September 15, 2022 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy May Be a New Standard of Care in Resectable NSCLC
Phoebe Starr
TOP - July 2022 Vol 15, No 4 published on July 20, 2022 in Lung Cancer
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Gathering and Assessing Social Determinants of Health for Improved Patient Outcomes
Meg Barbor, MPH
TOP - March 2021 Vol 14, No 2 published on March 11, 2021 in Healthcare Policy
Last modified: July 22, 2021